文献速递真实世界研究与卫生经济流行病学与生物统计

NHS健康检查项目未来成本效果与公平性:利物浦微观模拟建模

Future cost-effectiveness and equity of the NHS Health Check cardiovascular disease prevention programme: Microsimulation modelling using data from Liverpool, UK.
PubMed 文献 · PLoS Med · 2018-05-29

本研究采用IMPACTNCD动态随机微观模拟模型,基于利物浦数据模拟2017至2040年NHS健康检查项目的五种实施情景。结果显示当前实施方式(情景A)不太可能具有成本效果或公平性,而针对性实施(情景B)到2040年可能具有成本效果、2039年具有公平性;优化实施(情景C)到2030年可能具有成本效果、2040年节省成本;结合结构性干预(情景D和E)可更早节省成本并改善公平性。

要点

  • 当前NHS健康检查实施方式在利物浦不太可能具有成本效果或公平性。
  • 针对性实施到2040年可能具有成本效果,到2039年可能具有公平性。
  • 结合结构性干预可更早实现成本节省并改善公平性。

核心结论

  • 当前NHS健康检查实施方式不太可能具有成本效果或公平性。
  • 优化实施可能节省成本但不公平,针对性实施可能兼具成本效果和公平性。
  • 增加针对心血管危险因素的结构性政策可大幅改善公平性并产生成本节省。

研究设计与样本

  • IMPACTNCD动态随机微观模拟政策模型,校准至利物浦人口学、危险因素暴露和心血管流行病学数据。
  • 模拟2017至2040年五种情景,并与无NHS健康检查的反事实进行比较。

主要发现

  • 与无NHS健康检查相比,情景A的累计增量成本效果比(ICER)为11,000(95%不确定性区间 -270,000至320,000)英镑/质量调整生命年。
  • 情景B的ICER为1,500(-91,000至100,000),情景C为-2,400(-6,500至5,700),情景D为-5,100(-7,400至-3,200),情景E为-5,000(-7,400至-3,100)。
  • 情景B到2040年可能具有成本效果,到2039年可能具有公平性;情景C到2030年可能具有成本效果,到2040年可能节省成本。
  • 情景D和E分别到2021年和2023年可能节省成本,到2025年可能具有公平性。

临床怎么用

  • 在剥夺程度高和心血管疾病负担高的城市,当前NHS健康检查实施方式需重新评估。
  • 针对性实施联合结构性干预可能同时改善成本效果和公平性。

局限性

  • 分析仅明确建模了心血管疾病和糖尿病。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Aiming to contribute to prevention of cardiovascular disease (CVD), the National Health Service (NHS) Health Check programme has been implemented across England since 2009. The programme involves cardiovascular risk stratification-at 5-year intervals-of all adults between the ages of 40 and 74 years, excluding any with preexisting vascular conditions (including CVD, diabetes mellitus, and hypertension, among others), and offers treatment to those at high risk. However, the cost-effectiveness and equity of population CVD screening is contested. This study aimed to determine whether the NHS Health Check programme is cost-effective and equitable in a city with high levels of deprivation and CVD. METHODS AND FINDINGS: IMPACTNCD is a dynamic stochastic microsimulation policy model, calibrated to Liverpool demographics, risk factor exposure, and CVD epidemiology. Using local and national data, as well as drawing on health and social care disease costs and health-state utilities, we modelled 5 scenarios from 2017 to 2040: Scenario (A): continuing current implementation of NHS Health Check;Scenario (B): implementation 'targeted' toward areas in the most deprived quintile with increased coverage and uptake;Scenario (C): 'optimal' implementation assuming optimal coverage, uptake, treatment, and lifestyle change;Scenario (D): scenario A combined with structural population-wide interventions targeting unhealthy diet and smoking;Scenario (E): scenario B combined with the structural interventions as above. We compared all scenarios with a counterfactual of no-NHS Health Check. Compared with no-NHS Health Check, the model estimated cumulative incremental cost-effectiveness ratio (ICER) (discounted £/quality-adjusted life year [QALY]) to be 11,000 (95% uncertainty interval [UI] -270,000 to 320,000) for scenario A, 1,500 (-91,000 to 100,000) for scenario B, -2,400 (-6,500 to 5,700) for scenario C, -5,100 (-7,400 to -3,200) for scenario D, and -5,000 (-7,400 to -3,100) for scenario E. Overall, scenario A is unlikely to become cost-effective or equitable, and scenario B is likely to become cost-effective by 2040 and equitable by 2039. Scenario C is likely to become cost-effective by 2030 and cost-saving by 2040. Scenarios D and E are likely to be cost-saving by 2021 and 2023, respectively, and equitable by 2025. The main limitation of the analysis is that we explicitly modelled CVD and diabetes mellitus only. CONCLUSIONS: According to our analysis of the situation in Liverpool, current NHS Health Check implementation appears neither equitable nor cost-effective. Optimal implementation is likely to be cost-saving but not equitable, while targeted implementation is likely to be both. Adding structural policies targeting cardiovascular risk factors could substantially improve equity and generate cost savings.

来源:PLoS Med,查看原文。版权归原作者所有。

引用

  1. Kypridemos C, Collins B, McHale P, et al. Future cost-effectiveness and equity of the NHS Health Check cardiovascular disease prevention programme: Microsimulation modelling using data from Liverpool, UK. PLoS Med. 2018. PMID: 29813056. doi:10.1371/journal.pmed.1002573

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。